Results 241 to 250 of about 185,950 (370)

A rare case of type 2A von Willebrand disease with compound heterozygous mutation. [PDF]

Ann Hematol
Wang LJ, Gao Q, Pang B, Wu T, Zhang X, Fang H, Chen H, Cai H.   +7 more
europepmc   +1 more source

Homozygous gene conversion in von Willebrand factor gene as a cause of type 3 von Willebrand disease and predisposition to inhibitor development [PDF]

, 2001
Gurcharan K. Surdhar, M. S. Enayat, Sarah Lawson, Michael D. Williams, Frank G. H. Hill   +4 more
openalex   +1 more source

Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report

American Journal of Hematology, Volume 100, Issue 10, Page 1813-1827, October 2025.
ABSTRACT Hereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies.
Hanny Al‐Samkari, Raj S. Kasthuri, Hans‐Jurgen Mager, Jenny Y. Zhou, Marcelo M. Serra, Bethany T. Samuelson‐Bannow, Layla N. Van Doren, Jay F. Piccirillo, Marianne S. Clancy, Keith R. McCrae, Sonia M. Thomas, Antoni Riera‐Mestre, Allyson M. Pishko, Sarah Sewaralthahab, James R. Gossage, Vivek N. Iyer, Cedric Hermans, Adrienne Hammill, Ingrid Winship, Meir Mei‐Zahav, Annette von Drygalski, Scott Olitsky, Marie E. Faughnan   +22 more
wiley   +1 more source

Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study

, 1999
A. Rumley, G.D.O. Lowe, P M Sweetnam, J. W. G. Yarnell, R P Ford   +4 more
openalex   +1 more source

Recombinant factor VIIa (NovoSeven®) for post‐prostatectomy hemorrhage in a patient with type I von Willebrand disease [PDF]

, 2001
Michael D. Tarantino, Rozanne Aberle
openalex   +1 more source

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2‐Low Breast Cancer With Cancer‐Related Microangiopathic Hemolytic Anemia: A Case Report

Cancer Innovation, Volume 4, Issue 5, October 2025.
The diagnosis and treatment of acquired hemolytic anemia can be challenging. In breast cancer patients, it may be directly associated with the underlying malignancy (as an initial presentation or during disease progression). The diagnosis of cancer‐related microangiopathic hemolytic anemia (CR‐MAHA) is often delayed, and patients have a high mortality ...
Mengyuan Li, Mao Ding, Yukun Hou, Xuening Duan, Yuanjia Cheng, Ling Xu   +5 more
wiley   +1 more source

Contemporary trends in maternal outcomes during delivery hospitalizations among pregnancies complicated by von Willebrand disease-a cross-sectional analysis. [PDF]

Res Pract Thromb Haemost
Sarker MR, Wiley R, Khanna V, Friedman AM, Wen T.   +4 more
europepmc   +1 more source

Use of the collagen‐binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay [PDF]

, 2002
Anne Riddell, P. Vincent Jenkins, Ioana Nitu-Whalley, A. McCraw, Christine A. Lee, Simon Brown   +5 more
openalex   +1 more source

A Case of an Acquired Factor V Inhibitor Triggered by Levofloxacin and Ceftazidime and Effectively Treated With Clinical Pharmacist Assistance

Clinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT Acquired factor V inhibitor is a rare and clinically challenging condition that can manifest across a spectrum ranging from asymptomatic laboratory abnormalities to life‐threatening hemorrhagic episodes. This case reports a patient with antibiotic‐associated AFVI, who presents asymptomatically and may be managed conservatively with close ...
Chunjuan Zhao, Weibu Chen, Xueyan Chen
wiley   +1 more source

Refractory Acquired von Willebrand Disease Despite Successful Treatment of the Associated Lymphoma [PDF]

, 2002
Wendy Slattery, Douglas J. Rausch, Nabil F. Saba   +2 more
openalex   +1 more source